XLIFE SCIENCES AG (:XLS) Xlife Sciences: Date of publication Annual Report 2022
Transparency directive : regulatory news
|
Xlife Sciences AG / Key word(s): Annual Results Xlife Sciences AG (SIX: XLS) today announced that due to the change from the Munich Stock Exchange (unregulated market ['Freiverkehr'] to the regulated market of the SIX Swiss Exchange (SME Segment 'Sparks') and the related change of auditors, the company will publish its annual report 2021 newly on 29 April 2022. Financial calendar Annual Report 2022 Contact April 29, 2022 Information for journalists: IRF Reputation AG, Valentin Handschin, handschin@irf-reputation.ch Information for investors: Dennis Lennartz, dennis.lennartz@xlifesciences.ch Xlife Sciences AG
Talacker 35
8001 Zürich
Telefon: 0041 44 385 84 60
E-Mail: info@xlifesciences.ch
Internet: www.xlifesciences.ch
ISIN: CH0461929603
WKN: A2PK6Z
Börsen: SIX Swiss Exchange
About Xlife Sciences AG (SIX: XLS) Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit www.xlifesciences.ch Disclaimer Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements. End of ad hoc announcement |
| Language: | English |
| Company: | Xlife Sciences AG |
| Talacker 35 | |
| 8001 Zürich | |
| Switzerland | |
| Phone: | +41 44 385 84 60 |
| E-mail: | info@xlifesciences.ch |
| Internet: | www.xlifesciences.ch |
| ISIN: | CH0461929603 |
| Valor: | A2PK6Z |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1331497 |
| End of Announcement | EQS News Service |
|
|
1331497 21-Apr-2022 CET/CEST